Williams M H
Chest. 1975 Dec;68(6):765-8. doi: 10.1378/chest.68.6.765.
Thirty-five steroid-dependent asthmatic patients have been treated with an aerosol of triamcinolone acetonide for periods ranging from 8 to 26 months. Fourteen patients discontinued the oral use of steroids for the first time in from 2 to 19 years and throughout the period of treatment with aerosol, have not required any other steroid medication. Fifteen patients were able to discontinue oral use of steroids but have required one or more short supplemental courses of oral steroid treatment for exacerbations of asthma. Six patients have either continued to require oral steroid therapy, or their symptoms have been incompletely controlled by the aerosol. Steroid aerosols represent an important advance for the treatment of asthma. Small doses which do not suppress adrenal function and do not produce hyperadrenocorticism make it possible for most patients to eliminate or substantially reduce their requirement for oral steroid therapy.
35例激素依赖型哮喘患者接受了曲安奈德气雾剂治疗,治疗时间为8至26个月。14例患者在2至19年中首次停止口服类固醇药物,并且在使用气雾剂治疗期间,无需任何其他类固醇药物治疗。15例患者能够停止口服类固醇药物,但因哮喘发作需要一个或多个短期补充口服类固醇疗程。6例患者继续需要口服类固醇治疗,或者其症状未被气雾剂完全控制。类固醇气雾剂是哮喘治疗的一项重要进展。小剂量药物不会抑制肾上腺功能,也不会产生肾上腺皮质功能亢进,这使得大多数患者能够消除或大幅减少口服类固醇治疗的需求。